Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti
about
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim DatabaseIt Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting StentPharmacological inhibition of coronary restenosis: systemic and local approaches.Clinical efficacy and safety of cilostazol: a critical review of the literature.Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia).Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials.More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions.The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox".Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials.Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
P2860
Q28550517-52521B0D-18D9-4D21-BE1E-C0D3C130B104Q36299313-724FF7E2-EF62-42B5-835D-5B44866EC053Q38241974-2D41BBA0-5911-4037-9AB3-2E6C65157ABEQ38372990-7033694E-49FF-401E-972B-65470A2D1C9AQ39088761-4821343E-3BF2-4DF9-B99E-9C48B612BE7AQ39147420-EBD9D7B9-D03D-4039-91F5-2BA19EB04CF4Q40225108-C4F559CF-64AE-467E-96EE-C4B33DFB726FQ41875999-D2C409B9-3F77-4A6D-81BF-0CC16DCE46A4Q47709533-3BB4798B-9B42-4FE5-AC4A-DFBBD8B4F0C6Q55431233-D663BEB8-7412-4837-9071-7588B3A11A95Q55482069-8C0B2A5B-205F-444A-95F2-593C2A2359E6Q58768916-0CE01F0F-AEB2-4119-B086-B5BF57494811
P2860
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adjunctive cilostazol versus d ...... of Drug-Eluting Stents & Anti
@en
type
label
Adjunctive cilostazol versus d ...... of Drug-Eluting Stents & Anti
@en
prefLabel
Adjunctive cilostazol versus d ...... of Drug-Eluting Stents & Anti
@en
P2093
P1476
Adjunctive cilostazol versus d ...... of Drug-Eluting Stents & Anti
@en
P2093
Bon-Kwon Koo
Byoung-Eun Park
Eun Seok Shin
Han-Mo Yang
Hui-Kyoung Jeon
Hyo-Soo Kim
Hyun-Jae Kang
In-Ho Chae
Jay Young Rhew
Jin Joo Park
P304
P356
10.1016/J.JCIN.2013.04.022
P50
P577
2013-09-01T00:00:00Z